What's happening
This bill creates a Clinical Trial Access and Education Fund to provide grants for services that improve patient access to clinical trials, especially for those with life-threatening or disabling conditions.
Why it matters
Reduces financial barriers for patients. by covering ancillary costs such as travel, lodging, and other expenses related to clinical trial participation, making it easier for lower-income or geographically distant patients to enroll.
Targets underserved populations with life-threatening or disabling conditions. , potentially increasing diversity and representation in clinical research, which can lead to more generalizable results and better health outcomes for these groups.
Promotes education and navigation support. for patients and their families, helping them understand clinical trial options and enrollment processes, as well as assisting with insurance and logistical challenges that often prevent participation.
Establishes accountability and oversight. through required reporting and compliance with both state and federal laws, ensuring that grant funds are used effectively to enhance clinical trial access and that patient protections are in place.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Help Patients Join Clinical Trials
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Reported and committed to finance
- Referred to health
- Referred to health
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
4793
2023-2024 Regular Sessions
IN SENATE
February 14, 2023
Introduced by Sens. RIVERA, SEPULVEDA -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the public health law, in relation to establishing the clinical trial access and education fund
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The public health law is amended by adding a new section 2424 to read as follows:
§ 2424. Clinical trial access and education fund. 1. Definitions. For the purposes of this section, the following terms shall have the following meanings:
a. "Eligible applicant" means (i) a medical school that sponsors a clinical trial, (ii) a not-for-profit organization with experience and expertise working with patients with life-threatening or disabling conditions or diseases, (iii) a health care provider organization, association or society, (iv) a general hospital defined in article twentyeight of this chapter, (v) a county or city health department, or (vi) a municipality.
b. "Clinical trial" shall have the same meaning as in subdivision two-b of section forty-nine hundred of this chapter.
c. "Ancillary costs" means costs associated with participation in a clinical trial, including but not limited to costs for:
(i) travel;
(ii) lodging;
(iii) parking and tolls;
(iv) a travel companion to assist patients who are elderly, very young, or too ill to travel alone; and
(v) other costs considered appropriate jointly by the department, the service providing organization and the trial site.
2. Establishment of fund. There is hereby established within the department a clinical trial access and education fund. Subject to appro-
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD08047-01-3
priations, the department shall provide grants to eligible applicants on a competitive request for proposal basis to provide one or more of the following services to patients with life-threatening or disabling conditions or diseases, as such terms are defined in section forty-nine hundred of this chapter, to facilitate access to or education on clinical trials of treatments for the patient's condition or disease:
a. transportation services and lodging to provide patients with access to clinical trials or other related treatments while enrolled in a clinical trial or to access testing and other services to determine patient eligibility for a clinical trial;
b. patient outreach and education services to educate patients, their families and health care providers about the existence of and how patients may enroll in clinical trials, under section two hundred seven of this chapter; and
c. patient navigation services to help patients to determine if they are eligible for clinical trials, to help patients to enroll in clinical trials and to assist patients in dealing with insurance or other issues which serve as barriers to patient enrollment in clinical trials.
3. Applications. a. The commissioner shall establish an application process by which eligible applicants may apply for a grant under this section. The application shall include:
(i) the geographic area in which the services shall be provided;
(ii) a detailed description of the services to be provided;
(iii) applicant's experience working with patients with life-threatening or disabling conditions or diseases;
(iv) applicant's ability to provide patient outreach or clinical trial education and navigation services, or coordinate or provide transportation and lodging for patients; and
(v) any other information that the commissioner deems relevant and appropriate.
b. Eligible applicants shall:
(i) have experience and expertise working with patients with lifethreatening or disabling conditions or diseases;
(ii) provide patient outreach, education and health care navigation services;
(iii) collaborate with physicians, health care providers, and clinical trial sponsors to notify a prospective subject about the program when:
(1) the prospective subject consents to a clinical trial; and
(2) funding is available to provide the program for the clinical trial in which the prospective subject participates; and
(iv) reimburse subjects based on financial need to subjects whose income is at or below seven hundred percent of the federal poverty level, which shall include reimbursement for reasonable ancillary costs.
4. Institutional review board requirements. A reimbursement program under this section shall:
a. be approved by the institutional review board associated with the clinical trial; and
b. comply with applicable federal and state laws.
5. Reimbursement. Reimbursement to a subject of ancillary costs under the program:
a. does not constitute an undue inducement to participate in a clinical trial;
b. is not considered coercion or the exertion of undue influence to participate in a clinical trial; and
c. is meant to accomplish parity in access to clinical trials and remove barriers to participation in clinical trials for financially burdened subjects.
6. Reports. Grantees shall file an annual report with the commissioner, in such form and with such information and data as the commissioner prescribes detailing the expenditure of grant funds and summarizing the efforts undertaken to increase patient access to clinical trials.
7. Regulations. The commissioner shall make regulations reasonably necessary to implement the provisions of this section.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law, in relation to establishing the clinical trial access and education fund
Purpose
Establishes the clinical trial access and education fund to provide grants for certain services for patients with life-threatening or disa- bling conditions/diseases.
Summary of specific provisions
Section 1 amends the public health law by adding a new section 2424 as it relates to a clinical trial access and education fund. For the purpose of this bill, this section defines the terms "eligible appli- cants," "clinical trial," and "ancillary cost," in addition to estab- lishing the terms and conditions for patient participation, reporting requirements, and regulation requirements.
Section 2 provides the effective date.
Justification
New therapies to treat cancer and other life-threatening diseases are being developed at an increasing pace. Clinical trials are the most effective method of determining the benefits of experimental treatments and are critical to improving health care and mortality rates for patients with cancer and other life-threatening diseases.
A large number of pediatric enrollees in clinical trials led to the discovery of groundbreaking therapies and a survival rate of over 80% for childhood cancer. To achieve a similar rate of success for adults with cancer and other diseases, information and access to clinical trials must be made more widely available to patients and their treating health care providers.
A number of studies have looked at the reasons for low adult patient participation in clinical trials. One such study conducted by the University of California Davis' Cancer Center surveyed patients and physicians about clinical trial participation. Of the 276 patients surveyed, only 76 said they would participate in clinical trials if recommended by their physician. Of this, only 39 actually enrolled.
The two most common reasons why patients declined to participate were related to a desire for other treatments and the distance to the cancer center. The study authors made a series of recommendations to overcome these barriers including the need for greater physician and patient education on the status, availability, and benefits of clinical trials, as well as the need to address geographical issues that serve as strong deterrents to clinical trial access.
The Clinical Trial Access and Education Fund will address these major barriers identified by the clinical research and anecdotally from patients and providers in New York by providing grants to not-for-profit community groups, health care provider associations, and research centers that conduct clinical trials so they may provide and/or facili- tate patient navigation, transportation, lodging, and patient and provider education to achieve greater patient participation in clinical trials.
Legislative history
2013-2014: S6442
2015-2016: S8777
2017-2018: S1216
2019-2020: S932/A1035 Gottfried
2021-2022: S1169-A/A180-A Gottfried
Fiscal implications
None, subject to available appropriations.
Effective date
This act shall be effective immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.